Tradestie Institutional Equity Comparison Engine
CELU vs FGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FGEN Overall Edge
FGEN Captures Institutional Edge (3โ1 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to FibroGen, Inc (FGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical while CELU counters with relative strength in Options & Structure. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus FGEN at 61.4x Forward P/E and -499.1% operating margin (+774.8% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against FGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
FGEN
CELU N/M vs FGEN 61.4x Fwd P/E
Growth & Margin Winner
FGEN
Op Margin -254.0% vs -499.1% ยท YoY -5.3% vs +774.8%
Momentum & Technical Winner
FGEN
1Y -72.6% vs -28.8% ยท 52W Pos 2% vs 44%
Options & Structure Winner
CELU
BREAKDOWN (50th %ile IV) vs UNCLASSIFIED (N/A IV)
CELU
NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap
$15.2M
1M Return
-55.9%
1Y Return
-72.6%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 25.0
Fund 48.0
Flow 67.0
Mom 55.0
FGEN
NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap
$36.5M
1M Return
+16.57%
1Y Return
-28.84%
Forward P/E
61.4x
Unified AI Score
61.2 / 100
BUY
Tech 60.0
Fund 56.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CELU -72.6%
FGEN -28.84%
Spread: +40.2 pp (FGEN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CELU TTM Op. Margin: -254.0%
FGEN TTM Op. Margin: -499.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELU vs FGEN. Trailing 12-month operating profitability (CELU -254.0% vs FGEN -499.1%) and valuation multiples (CELU N/M vs FGEN 61.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CELU | FGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.2M | $36.5M | Larger Scale | FGEN |
| Trailing P/E Ratio Valuation | N/M | 61.4x | Lower Multiple | FGEN |
| Forward P/E Ratio Valuation | N/M | 61.4x | Lower Multiple | FGEN |
| Revenue Growth (YoY) Growth | -5.3% | +774.8% | Higher Growth | FGEN |
| Operating Margin (TTM) Profitability | -254.0% | -499.1% | Higher Margin | CELU |
| Net Profit Margin Profitability | -245.7% | 2598.9% | Higher Margin | FGEN |
| Return on Equity (ROE) Capital Efficiency | -6367.2% | -1015.8% | Higher ROE | FGEN |
| 52-Week Range Position Momentum | 2% ($0โ$3) | 44% ($0โ$22) | Stronger Trend | FGEN |
| Beta / 30D Volatility Risk Regime | 2.01ฮฒ ยท 135% Vol | -20.79ฮฒ ยท 102% Vol | Lower Realized Risk | FGEN |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 61.2 / 100 (BUY) | Higher Composite | FGEN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CELU vs FGEN Buy Guide
CELU
BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
FGEN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CELU nor FGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.